

5 mg | 10 mg
Metozolv[®] ODT
 (metoclopramide HCl)
 Orally Disintegrating Tablets

Reimbursement Support

Reimbursement Helpline
1-877-305-4ODT(4638)
www.MetozolvODT.com

This free support service helps Metozolv ODT customers get answers to third party payer coverage questions. Our staff can also assist with negotiating appeals on behalf of your patients should their claims be denied. The Helpline can also provide a timely solution to issues you may encounter either before or after submitting a patient claim for reimbursement, such as:

- Receive current reimbursement policies for private payers, Medicaid, and Medicare
- Verify individual patient coverage
- Conduct prior authorizations
- Verify insurance coverage associated with the patient assistance program
- Manage negotiation of appeals on denied claims
- Receive customized information to assist with coverage or appeals

Reimbursement Made Easy

STEP 1 Fill out the Form	Download the Patient Information Form from our web site and fill it out.	Reimbursement Online www.MetozolvODT.com
STEP 2 Get Questions Answered	For questions regarding the Patient Information Form and reimbursement support, call the Helpline. <ul style="list-style-type: none"> • Trained reimbursement analysts can answer your questions • Open Monday through Friday, 8:30 AM to 5:30 PM Eastern Standard Time 	Reimbursement Helpline 1-877-305-4ODT(4638)
STEP 3 Submit the Completed Form	Completed Patient Information Forms must be submitted via this fax number.	Reimbursement Fax Line 1-800-387-9718

IMPORTANT SAFETY INFORMATION

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

Please see accompanying full Prescribing Information for METOZOLV ODT, including **BOXED WARNING**.

